Ratings Aurora Cannabis Inc.

Equities

ACB

CA05156X8504

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-07 pm EDT			5-day change	1st Jan Change
9.15 ^CAD	+0.55%		-27.67%	+40.77%

Apr. 30	Health Care Flat Amid Mixed Earnings -- Health Care Roundup	DJ
Apr. 30	TSX Down More Than 1% Today and More Than 2% For April, Having Hit Record Highs Earlier In the Month; But Cannabis Stocks Hit a High	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AURORA CANNABIS INC.	+40.77%	364M		D+
DONG-E-E-JIAO CO.,LTD.	+43.96%	6.34B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.56%	4.51B		C+
TASLY PHARMACEUTICAL GROUP CO., LTD	-6.52%	3.29B		B-
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+5.47%	3.2B		C
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-0.76%	2.59B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+56.34%	2.09B		-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.11%	1.76B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+2.93%	1.7B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.02%	1.62B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes